Back to Diseases

Vitiligo (Leukoderma)

An authoritative clinical profile of Vitiligo covering EuroGuiDerm 2021 guidelines, CD8+ cytotoxic T-cell melanocyte destruction mechanics, narrowband UVB phototherapy safety boundaries, and systemic autoimmune screening requirements.

Consensus-GuidanceReviewed: Jul 31, 2026

Editorial review complete

Independent clinical validation is pending.

Validation pending

Quick Reference Facts

System AffinityGeneral
Diagnostic StandardClinical evaluation & serum biomarkers
Urgency Levelroutine
Evidence GradeConsensus-Guidance

Visual guide

Understanding skin pigment
Living with vitiligo
A closer look at pigment

In simple words

Vitiligo is a chronic autoimmune depigmenting skin disorder characterized by selective destruction of epidermal melanocytes, resulting in chalk-white macules and patches [D0036-KEYNOTES, CIT-0060]. EuroGuiDerm 2021 guidelines prioritize halting active progression and inducing re-pigmentation.

What it means

An acquired autoimmune disease affecting 0.5-2% of the global population, categorized into non-segmental (generalized, acrofacial, universal) and segmental vitiligo, driven by CD8+ T-cell-mediated melanocyte apoptosis.

Common causes

  • Autoimmune destruction of functional melanocytes mediated by CD8+ cytotoxic T-cells producing IFN-γ and CXCL10 [D0036-KEYNOTES, CIT-0060]
  • Melanocyte intrinsic oxidative stress susceptibility combined with organelle dysfunction
  • Genetic heritability (HLA-A2, HLA-DR4, NLRP1) interacting with environmental trauma (Koebner phenomenon)

Risk Factors

  • Personal or family history of vitiligo or co-occurring autoimmune conditions (Hashimoto's Thyroiditis, Graves' Disease, Alopecia Areata, Pernicious Anemia, Addison's Disease)
  • Physical skin trauma, friction, or chemical exposure (monobenzone, phenols)
  • Psychological stress aggravating oxidative stress cascades

Common symptoms

  • Asymptomatic, well-circumscribed milk-white or chalk-white macules and patches [D0036-KEYNOTES, CIT-0060]
  • Trichrome or quadrichrome lesions with varying shades of depigmentation, and leukotrichia (depigmented hair within lesions)
  • Predilection for sun-exposed areas (face, hands), periorificial zones (eyes, mouth), extensor surfaces (wrinkles, knees), and flexural friction folds

Lifestyle & diet support

Apply broad-spectrum sunscreen (SPF 30+) to depigmented patches to prevent sunburn, avoid tight friction-causing clothing (minimizing Koebnerization), and manage stress.

Treatment Approaches

Conventional Management

Management includes topical corticosteroids (high-potency), topical calcineurin inhibitors (tacrolimus, pimecrolimus), targeted narrowband UVB (NB-UVB) phototherapy, systemic mini-pulse corticosteroids (for rapidly spreading active disease), and surgical autologous melanocyte transplantation for stable localized lesions [CIT-0060].

Homeopathic Approach

Homeopathic remedies (such as Hydrocotyle Asiatica, Arsenicum Sulfuratum Flavum, Silicea, Sulphur, Sepia) serve as supportive constitutional care to modulate systemic immune hyper-reactivity, reduce oxidative stress, and support skin health alongside dermatological care.

Frequently Asked Questions

Rapid spreading of multiple new white patches over weeks (ACTIVE PROGRESSIVE VITILIGO), or co-occurrence of severe fatigue, dizziness, and low blood pressure (ADDISON'S DISEASE CRISIS) or eye pain/vision changes (VOGT-KOYANAGI-HARADA SYNDROME) requires URGENT DERMATOLOGICAL / ENDOCRINE EVALUATION [D0036-EMERGENCY-LIMITS, CIT-0060]. Active spreading requires prompt stabilization.
NO. Homeopathy MUST NOT be used to replace diagnostic Wood's lamp evaluation, thyroid autoantibody screens, or supervised NB-UVB phototherapy [D0036-REGULATORY-LIMITS].
Homeopathy serves as complementary constitutional care while patients remain under standard dermatological guidance, Wood's lamp tracking, and phototherapy protocols [D0036-REGULATORY-LIMITS].
Clinical & academic detailShow detail

Diagnosis & tests

Investigation Protocol

Diagnosed by clinical examination enhanced by Wood's lamp fluorescence (accentuating bright blue-white epidermal depigmentation). Screening includes thyroid peroxidase autoantibodies (TPO), serum TSH, CBC, and fasting blood glucose [CIT-0060].

Differential Diagnosis

Differentiate Vitiligo from Pityriasis Alba, Tinea Versicolor (fungal scaling), Post-Inflammatory Hypopigmentation, Leprosy (hypopigmented anaesthetic macules), Nevus Depigmentosus, and Chemical Leukoderma.

Differential Diagnosis Matrix

Differential Diagnosis Overview

Differentiate Vitiligo from Pityriasis Alba, Tinea Versicolor (fungal scaling), Post-Inflammatory Hypopigmentation, Leprosy (hypopigmented anaesthetic macules), Nevus Depigmentosus, and Chemical Leukoderma.

Reference Citations & Evidence Sources

Clinical Guidelines & Consensus Statements
  • CIT-0060Taïeb A., Alomar A., Böhm M.. "EuroGuiDerm Guideline on the Diagnosis and Management of Vitiligo." Journal of the European Academy of Dermatology and Venereology (2021).DOI PubMed
Materia Medica & Keynotes
  • CIT-0004Hahnemann S.. "Materia Medica Pura." Adolph Arnold (1811).
  • CIT-0005Kent J. T.. "Lectures on Homoeopathic Materia Medica." Boericke & Tafel (1905).
  • CIT-0006Boericke W.. "Pocket Manual of Homoeopathic Materia Medica." Boericke & Runyon (1901).

No clinical connections registered for this topic.

Patient Clinical Support

Seeking Expert Consultation?

Book an online video session with Dr. Narayan Jethwani to get an individualized constitutional homeopathic protocol tailored to your case.

Book Consultation

Medical Safety Disclaimer

All content on the Homeo Healthcare platform is strictly for educational purposes and is not personal medical advice, diagnosis, or treatment. Homeopathic remedy considerations are provided for clinician review or require individualized consultation with a qualified physician. Never delay seeking professional medical advice or emergency medical care due to content you have read on this website.